-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Two patients with advanced Hodgkin's lymphoma developed resistance to all therapies, and the doctor told them that hospice care might be their last choice.
Natural killer cells are the innate immune cells that exist in the human body.
The NK cell therapy used in this clinical trial is a different approach.
▲The mode of action of the combination of innate cell binders and NK cells (picture source: Affimed official website)
In this open-label, phase 1 clinical trial, a total of 4 patients received treatment with NK cells combined with the innate cell binder AFM13.
▲The status and treatment results of the 4 patients undergoing treatment (picture source: reference [1])
Reference materials:
[1] Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13.
[2] Actualizing the Untapped Potential of the Innate Immune System.